Institute of Human Virology Nigeria

Top Virologists to Meet in Monaco to Tackle Ongoing Pandemic Challenges and Emerging Viral Threats

Retrieved on: 
Wednesday, October 11, 2023
Partnership, Emergent virus, Doctor of Philosophy, University, Death, University of Maryland, Baltimore, CSM, MD, University of Maryland School of Medicine, Virology, Institute of Human Virology Nigeria, Viral disease, Emeritus, Yale School of Public Health, Prince, HIV, Entrepreneurship, Global Virus Network, AIDS, Virus, Friends, Maryland School, GVN, Challenge, Public health, Vaccine, Management, Arbovirus, EU

This coalition of the world’s leading medical virology researchers, who work together to prevent illness and death from viral disease, will hold high-level scientific sessions examining pandemic preparedness and current threats.

Key Points: 
  • This coalition of the world’s leading medical virology researchers, who work together to prevent illness and death from viral disease, will hold high-level scientific sessions examining pandemic preparedness and current threats.
  • A special GVN-CSM joint session will focus specifically on preparedness in European Union countries and will be attended by the High Patronage of H.S.H.
  • Prince Albert II of Monaco, among other dignitaries.
  • Lander Professor of Public Health, Yale School of Public Health as its next GVN President, effective November 1, 2023.

Global Virus Network (GVN) Leaders Publish STAT Op-Ed with a U.S. Government Call to Action and Road Map for the Future of COVID-19

Retrieved on: 
Tuesday, January 31, 2023
University, MPH, Global Virus Network, Plan, COVID, SARS-CoV-2, University of Maryland, Baltimore, International Partnership on Avian and Pandemic Influenza, Centers for Disease Control and Prevention, Human, Entrepreneurship, CDC, Virology, Foreign policy of the Joe Biden administration, Associate, Center of excellence, USF, Internal medicine, Network affiliate, Institute of Human Virology Nigeria, Politics, Scientific Leadership, Innovation, GVN, COVID-19, Policy, Infection, Probability, Public, University of Maryland School of Medicine, Animal, Risk, Maryland School, Disease, Division, Administration, Doctor of Philosophy, Vaccine, Management, MD, Medicine, Science

This challenges the Biden Administration's COVID Winter Preparedness Plan and the Centers for Disease Control and Prevention's (CDC) recommendation of some exposure-avoidance for everyone.

Key Points: 
  • This challenges the Biden Administration's COVID Winter Preparedness Plan and the Centers for Disease Control and Prevention's (CDC) recommendation of some exposure-avoidance for everyone.
  • "Science is telling us that, for most people who aren't at high risk, COVID-19 is becoming a common airborne illness of manageable severity.
  • Early in his term, President Biden appointed his slate of science advisers with the promise that they would lead with 'science and truth.
  • '  They now have the opportunity to demonstrate that sound science and good politics can go hand in hand."

Fujifilm and Qure.ai Join Hands With IHVN to Accelerate TB Screening in Rural Nigerian Communities

Retrieved on: 
Friday, August 12, 2022
Technology, Health, Radiology, Artificial Intelligence, Philanthropy, Other Science, Research, Medical Devices, Software, Infectious Diseases, General Health, Foundation, Hardware, Science, Death, Federal Ministry of Science and Technology, Heart failure, Oyo, Pneumonia, CEO, X-ray, Algorithm, Diagnosis, Technology, AI, Institute of Human Virology Nigeria, Leprosy, Leadership, Triage, Research, Tuberculosis, Office of the National Coordinator for Health Information Technology, University of Maryland, Baltimore, Founder, Health, Contact tracing, United States Agency for International Development, Federal Ministry of Health (Nigeria), International development, Partnership, National Tuberculosis Institute, Infection, COPD, Electricity, WHO, Virology, USAID, HIV, Solution, Party, TB, Medical imaging, Medical device, Pharmaceutical industry, Fujifilm

The partnership has enabled USAID funded IHVN to deploy ultra-portable X-ray machines embedded with AI for active case finding in Nigerian rural communities.

Key Points: 
  • The partnership has enabled USAID funded IHVN to deploy ultra-portable X-ray machines embedded with AI for active case finding in Nigerian rural communities.
  • Through our efforts (rural dwellers in communities with difficult terrains have been reached with TB care).
  • Our partnership with Fujifilm and Qure.ai for AI enabled TB screening is our most recent initiatives towards community outreach.
  • Together IHVN, Fujifilm and Qure.ai aim to strengthen the systems and structures for tuberculosis detection, treatment, and notification in rural Nigeria.

GLOBAL VIRUS NETWORK (GVN) CONVENES FIRST-OF-ITS-KIND CONFERENCE TO EVALUATE THE PUBLIC HEALTH MAGNITUDE OF LONG COVID AND DEFINE A GLOBAL RESEARCH ROADMAP TO ADDRESS THE CRISIS

Retrieved on: 
Friday, July 22, 2022
Virus, Diabetes, Diagnosis, Severe acute respiratory syndrome coronavirus 2, Time, Infection, University, GVN, International Partnership on Avian and Pandemic Influenza, Intelligence, Foundation, Insomnia, Harvard T.H. Chan School of Public Health, Network affiliate, Risk factor, Research, Science, Frustration, University of Maryland, Baltimore, Immunology, Survivor, Cardiovascular disease, Biomarker, Vaccination, Solution, Government budget balance, Associate, Respiratory system, Risk, Syndrome, Public health, Multimedia, Vaccine, Conference, Type 2 diabetes, Area studies, Inflammation, Maryland School, Long, Institute of Human Virology Nigeria, Disease, COVID, Patient, Excellent, Innovation, Man, Global Virus Network, Virology, Prevalence, University of Maryland School of Medicine, Pharmaceutical industry, COVID-19

BALTIMORE, July 22, 2022 /PRNewswire/ -- The Global Virus Network (GVN), a coalition of world leading medical virology research centers, yesterday concluded a two-day gathering on the 'Science of Long COVID.' The first-of-its-kind conference reviewed the wealth of cohort data on long COVID, constructed a framework to characterize and define the conditions, and identified the most critical and urgent areas of research needed to better understand, diagnose, and treat this developing public health crisis.

Key Points: 
  • Conference speakers from around the world focused on the vast public health implications of this highly prevalent condition.
  • Vaccination has reduced the numbers of individuals with long COVID respiratory disease, while new COVID variants show milder effects.
  • Risk factors for long COVID include Type 2 Diabetes, SARS-CoV-2 RNAemia, Epstein-Barr virus viremia, microclots, protein misfolding, and both pre-existing and disease-specific autoimmunity.
  • The GVN and the leads of its long COVID Task Force agree that long COVID is an opportunity to create a cohesive, global public health response unlike any other historical effort.

Kane Biotech Announces First Quarter 2022 Financial Results

Retrieved on: 
Thursday, May 26, 2022
CEO, Assistant, Company, Howard Brody, Certification, Doctor of Philosophy, Patient, TSX Venture Exchange, SEDAR, Clinical trial, UTMB, Center for Biofilm Engineering, Maryland School, Biofilm, Â, Investor, Research, FDA, STEM, KNE, Intellectual property, University, Safety, Financial statement, Institute of Human Virology Nigeria, LLC, Growth, ISO, MD, Virology, GLOBE, Online gambling, Medical device, Pharmaceutical industry, Amazon

WINNIPEG, Manitoba, May 26, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the Company or Kane Biotech), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its first quarter 2022 financial results.

Key Points: 
  • WINNIPEG, Manitoba, May 26, 2022 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the Company or Kane Biotech), a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms, today announced its first quarter 2022 financial results.
  • Gross profit for the first quarter of 2022 was $183,621, an increase of 11% compared to $165,876 for the quarter ended March 31, 2021.
  • Detailed financial information about Kane Biotech can be found in its March 31, 2022.
  • Kane Biotech is pleased to invite all interested parties to participate in a conference call on Thursday, May 26, 2022 at 4:30pm ET during which time the results will be discussed.

Kane Biotech Announces New Collaboration Agreements for Prosthetic Joint Infection, expanding its DispersinB® applications

Retrieved on: 
Thursday, February 10, 2022
Bacteriophage, GLOBE, Department, Intellectual property, TSX Venture Exchange, UTMB, Rehabilitation, Research and development, Mortality, Faculty, Howard Brody, Assistant, R-21, Kane, Infection, Leadership, Institute of Human Virology Nigeria, Student, FDA, NIH, Patient, National, University, Crossref, Biofilm, CEO, Therapy, Virology, Vaccine, Virus, Maryland School, Orthopedic surgery, Disease, MD, PubMed, Army Medical Department (United States), Pharmaceutical industry, Research

In one study, the five-year mortality for prosthetic joint infections is over 20% [2].

Key Points: 
  • In one study, the five-year mortality for prosthetic joint infections is over 20% [2].
  • We are highly optimistic of advancing this field scientifically and clinically for the benefit of patients across the globe said Marc Edwards, CEO of Kane Biotech.
  • Dr. Nanda Yakandawala, Vice President of Research and Development at Kane, in collaboration with Dr. Doub and Josh Wenke, Ph.
  • StrixNB, DispersinB, Aledex, bluestem, bluestem, silkstem, goldstem, coactiv+, coactiv+, DermaKB and DermaKB Biofilm are trademarks of Kane Biotech Inc.

Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19

Retrieved on: 
Monday, January 10, 2022
Clinical trial, SEC, Safety, SAN, Drug development, LinkedIn, Infection, MBBS, Cancer, Goal, Patient, Research, Adult, Annual report, Asthma, Adrenaline, NIH, COVID-19, Naloxone, Food, Review, Patent, Opioid overdose, Degenerative disease, Principal, Private Securities Litigation Reform Act, Mutagenesis, Company, Institute of Human Virology Nigeria, Fast Track, Nasdaq, University of Maryland School of Medicine, ADMP, Communication, Form 10-K, University, Maryland School, Intellectual property, FDA, Virology, Twitter, GLOBE, Emergency, Division, Stanford University, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Allergy, Anaphylaxis, EUA, Pharmaceutical industry, Medicine, 4-Hydroxy-TEMPO, Hans-Olov Adami

SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.

Key Points: 
  • SAN DIEGO, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.
  • Tempol as an oral antiviral and anti-inflammatory agent may be an important countermeasure, if proven safe and effective in this trial.
  • We are thus applying for Fast Track designation to the FDA to expedite the regulatory approval pathway for Tempol.
  • There are no assurances that the FDA will grant Fast Track designation for the Companys Tempol product candidate.

American Gene Technologies Appoints Dr. Robert R. Redfield as Special Advisor to the CEO

Retrieved on: 
Wednesday, September 15, 2021
PKU, CDC, Cancer, Food, Virology, Maryland Department of Natural Resources, Criticism of the Food and Drug Administration, ClinicalTrials.gov, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Quality of life, FDA, Inherited disorders of trafficking, University, HIV/AIDS, Technology, National, Orphan, Immune system, Patient, HIV, Infection, Clinical trial, UNAIDS, Maryland Department of Health, Institute of Human Virology Nigeria, Degenerative disease, Maryland School, COVID-19, University of Maryland School of Medicine, Person, Center, AGT, Population, Diagnosis, Korea Disease Control and Prevention Agency, Research, Advisory Council, Medical device, Pharmaceutical industry, Vaccine

ROCKVILLE, Md., Sept. 15, 2021 /PRNewswire-PRWeb/ -- American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of the Institute for Human Virology, as special advisor to AGT CEO Jeff Galvin.

Key Points: 
  • ROCKVILLE, Md., Sept. 15, 2021 /PRNewswire-PRWeb/ -- American Gene Technologies (AGT) announces the appointment of Dr. Robert R. Redfield, former director of the Centers for Disease Control and Prevention (CDC) and co-founder of the Institute for Human Virology, as special advisor to AGT CEO Jeff Galvin.
  • Dr. Redfield is well known for his decades of dedicated work in virology, immunology and clinical research.
  • "It's a great honor to have Bob back on board," said AGT CEO Jeff Galvin.
  • Bob's passion for public service is matched only by his devotion to the cause of finding a cure for HIV.

Adamis Pharmaceuticals Doses First Patients in Phase 2/3 Clinical Trial for Tempol in the Treatment of COVID-19

Retrieved on: 
Thursday, September 2, 2021
ADMP, COVID, Naloxone, SEC, Research, COPD, Intellectual property, Review, Infection, Hypertension, Safety, Institute of Human Virology Nigeria, Patent, Form 10-K, Virology, Degenerative disease, University, Diabetes, MBBS, Stanford University, Asthma, National, DSMB, Adult, Principal, Opioid overdose, Vaccination, Chronic kidney disease, Patient, Anaphylaxis, Adrenaline, COVID-19, Hospital, Government, Nasdaq, Division, Emergency, Allergy, Goal, Maryland School, SAN, FDA, Obesity, Company, Private Securities Litigation Reform Act, Annual report, Cancer, GLOBE, University of Maryland School of Medicine, NDA, Inflammation, News, NIH, Pharmaceutical industry

Tempol as an oral antiviral and anti-inflammatory may be an important countermeasure if proven safe and effective in this trial.

Key Points: 
  • Tempol as an oral antiviral and anti-inflammatory may be an important countermeasure if proven safe and effective in this trial.
  • The data from Israel should be a wake-up call to the U.S. and the rest of the world.
  • Patients randomized to Tempol (n=124), will receive 800mg daily in two divided doses of 400mg for up to 21 days.
  • Tempol is in development for the treatment of patients with COVID-19 and a Phase 2/3 clinical trial is underway.